论文部分内容阅读
目的 通过血清学检测以探讨GST-π、sIgA和Ferr,对肝脏良恶性占位性病变鉴别诊断价值。方法血清GST-π参照本室建立的双抗体夹心ELISA法进行检测,sIgA和Ferr采用RIA法进行检测。 结果 肝癌组(n=38)血清GST-π、sIgA和Ferr含量均值分别为51.05±46.51 mg/L,52.7±31.3 mg/L和394.7±202μg/L。显著高于正常对照组(n=73)和肝良性占位性疾病组(n=24)。其阳性率分别为90.6％,85.7％和54.7％。对AFP阴性肝癌也有84.6％,81.2％和34.6％的检出率。 结论 GST-π、sIgA检测是辅以AFP对肝癌临床诊断有较大帮助的肿瘤标志物。可显著提高AFP阴性肝癌的检出率。对肝良恶性占位性疾病的鉴别诊断有很大的帮助。
Objective To investigate the differential diagnostic value of GST-π, sIgA and Ferr in the diagnosis of benign and malignant liver lesions by serological tests. Methods Serum GST-π was detected by double-antibody sandwich ELISA in our laboratory. SIgA and Ferr were detected by RIA. Results The serum levels of GST-π, sIgA and Ferr in hepatocellular carcinoma (n = 38) were 51.05 ± 46.51 mg / L, 52.7 ± 31.3 mg / L and 394.7 ± 202 μg / L, respectively. Was significantly higher than the normal control group (n = 73) and benign liver space occupying disease group (n = 24). The positive rates were 90.6%, 85.7% and 54.7% respectively. The detection rate of AFP negative liver cancer was 84.6%, 81.2% and 34.6%. Conclusion GST-π, sIgA test is a tumor marker assisted by AFP in the clinical diagnosis of liver cancer. Can significantly improve the detection rate of AFP-negative liver cancer. The differential diagnosis of benign and malignant liver diseases have a great help.